山東誠匯醫(yī)藥集團有限公司成立于2002年6月，注冊資本1.3億元，總部位于四面荷花三面柳,一城山色半城湖的歷史文化名城-山東濟南。是一家專注于醫(yī)藥原料藥、中間體、精細化工產(chǎn)品研發(fā)、生產(chǎn)、銷售及服務一體的高新技術企業(yè)，并致力于MAH、CDMO、獸藥、農(nóng)化等領域的新技術研發(fā)及應用。集團現(xiàn)擁有1個研發(fā)中心-山東誠創(chuàng)藍海醫(yī)藥科技有限公司，1個原料藥廠-山東誠匯雙達藥業(yè)有限公司及兩個醫(yī)藥中間體生產(chǎn)基地，現(xiàn)有職工1000余人，研發(fā)團隊300余人。
產(chǎn)品概況
GMP
鹽酸利多卡因、利多卡因、鹽酸丁卡因、丙胺卡因、塞來昔布、舒更葡糖鈉、奧扎格雷鈉、拉西地平、鹽酸烏拉地爾
I狀態(tài)富馬酸伏諾拉生、克立硼羅 、鹽酸羅哌卡因、丁卡因、鹽酸布比卡因、鹽酸阿替卡因
上報CEP米屈肼（已獲批）、鹽酸羅哌卡因（在審評）、鹽酸阿替卡因（在審評）
US-DMF鹽酸丙胺卡因、丁卡因、鹽酸普莫卡因、富馬酸伏諾拉生
在研來特莫韋、蘆可替尼、非奈利酮、瑪巴洛沙韋、阿帕他胺、他達拉非、氟雷拉納、阿福拉納、沙羅拉納等
*All our products are not offered in countries where valid patents exist. All responsibility with repect to third parties patent rights in specific countries lies exclusively with the buyers.
產(chǎn)品明細
| Product Name | 產(chǎn)品名稱 | CAS |
| *Vonoprazan Fumarate | 富馬酸伏諾拉生 |
1260141-27-2
881681-01-2
|
| *Letermovir | 來特莫韋 | 917389-32-3 |
| *Dapagliflozin propanediol monohydrate | 達格列凈一水丙二醇 | 960404-48-2 |
| *Crisaborole | 克立硼羅 | 906673-24-3 |
| Prilocaine | 丙胺卡因 | 721-50-6 |
| Lidocaine hydrochloride | 鹽酸利多卡因 | 6108-05-0 |
| Lidocaine | 利多卡因 | 137-58-6 |
| Ozagrel sodium | 奧扎格雷鈉 | 189224-26-8 |
| Celecoxib | 塞來昔布 | 169590-42-5 |
| Ropivacaine hydrochloride | 鹽酸羅哌卡因 | 132112-35-7 |
| Sugammadex sodium | 舒更葡糖鈉 | 343306-79-6 |
| Tetracaine hydrochloride | 鹽酸丁卡因 | 136-47-0 |
| Tetracaine | 丁卡因 | 94-24-6 |
| Prilocaine hydrochloride | 鹽酸丙胺卡因 | 1786-81-8 |
| Pramoxine hydrochloride | 鹽酸普莫卡因 | 637-58-1 |
| Meldonium | 米屈肼 | 86426-17-7 |
| Bupivacaine hydrochloride | 鹽酸布比卡因 | 73360-54-0 |
| Bupivacaine | 布比卡因 | 2180-92-9 |
| Articaine hydrochloride | 鹽酸阿替卡因 | 23964-57-0 |
| Tadalafil | 他達那非 | 171596-29-5 |
| *Apalutamide | 阿帕他胺 | 956104-40-8 |
| *Baloxavir Marboxil | 瑪巴洛沙韋 | 1985606-14-1 |
| *Fluralaner | 氟雷拉納 | 864731-61-3 |
| *Afoxolaner | 阿福拉納 | 1093861-60-9 |
| *Sarolaner | 沙羅拉納 | 1398609-39-6 |
| *Ruxolitinib | 蘆可替尼 | 941678-49-5 |
| *Finerenone | 非奈利酮 | 1050477-31-0 |
| *Upadacitinib | 烏帕替尼 | 1310726-60-3 |
| Ozenoxacin | 奧澤沙星 | 245765-41-7 |
| Donepezil hydrochloride | 鹽酸多奈哌齊 | 120011-70-3 |
| Levobupivacaine hydrochloride | 鹽酸左布比卡因 | 27262-48-2 |
| Dibucaine hydrochloride | 鹽酸地布卡因 | CAS：61-12-1 |
| Mepivacaine hydrochloride | 鹽酸甲哌卡因 | 1722-62-9 |
| Medetomidine hydrochloride | 鹽酸美托咪啶 | 86347-15-1 |
| Dyclonine hydrochloride | 鹽酸達克羅寧 | 536-43-6 |
| Dienogest | 地諾孕素 | 65928-58-7 |
| Altrenogest | 烯丙孕素/四烯雌酮 | 850-52-2 |
| Brexanolone | 5alpha-孕甾-3alpha-醇-20-酮 | 516-54-1 |
| Metoclopramide | 甲氧氯普胺（胃復安） | 364-62-5 |
| Brinzolamide | 布林佐胺 | 138890-62-7 |
| Terbinafine hydrochloride | 鹽酸特比萘芬 | 78628-80-5 |
| Mexidole | 美昔得樂 | 127464-43-1 |
| Dexmedetomidine hydrochloride | 鹽酸右美托咪定 | 145108-58-3 |
| Nadifloxacin | 那氟沙星 | 124858-35-1 |
|
富馬酸伏諾拉生中間體 Vonoprazan Fumarate Intermediates |
||
| 5-(2-fluorophenyl)-1H-Pyrrole-3-carboxaldehyde | 5-(2-氟苯基)-1H-吡咯-3-甲醛 | 881674-56-2 |
| Pyridine-3-sulfonyl chloride hydrochloride | 吡啶-3-磺酰氯 | 16133-25-8 |
|
達格列凈中間體 Dapagliflozin Intermediates |
||
| 5-bromo-2-chloro-4’-ethoxydiphenylmethane | 5-溴-2-氯-4’-乙氧基二苯甲烷 | 461432-23-5 |
| [(2R,3R,4R,5S,6S)-3,4,5-triacetyloxy-6-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]oxan-2-yl]methyl acetate | (2R,3R,4R,5S,6S)-2-(乙酰氧基甲基)-6-(4-氯-3-(4-乙氧基芐基)苯基)四氫-2H-吡喃-3,4,5-三yl 三乙酸酯 | 461432-25-7 |
|
來特莫韋中間體
Letemovir Intermediates
|
||
|
2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)
-2-oxo-1,2,3,4-tetrahydroquinazolin-4-yl) acetic acid methyl ester
|
2-(8-氟-3-(2-甲氧基-5-(三氟甲基)苯基)-2-氧代-1,2,3,4-四氫喹唑啉-4-基)乙酸甲酯 | 917389-21-0 |
| 1-(3-Methoxyphenyl)Piperazine Hydrochloride | 1-(3-甲氧基苯基)哌嗪鹽酸鹽 | 16015-70-6 |
|
克立硼羅中間體
Crisaborole Intermediates
|
||
| 2-bromo-5-hydroxybenzaldehyde | 2-溴-5-羥基苯甲醛 | 2973-80-0 |
| 4-[4-bromo-3-(hydroxymethyl)phenoxy]benzonitrile | 4-[4-溴-3-(羥基甲基)苯氧基]苯甲腈 | 906673-45-8 |
| [2-bromo-5-(4-cyanophenoxy)phenyl]methyl acetate | 2-溴-5-（4-氰基苯氧基）乙酸芐酯 | 2227126-09-0 |
|
瑪巴洛沙韋中間體
Baloxavir Marboxil Intermediates
|
||
| (R)-7-(benzyloxy)- 3,4,12,12a-tetrahydro- 1H-[1,4]oxazino[3,4- c]pyrido[2,1-f][1,2,4]- triazine-6,8-dione | (R)-7-(芐氧基)-3,4,12,12A-四氫-1H-[1,4]噁嗪[3,4-C]吡啶并[2,1-F] [1,2,4]三嗪-6,8二酮（巴沙洛韋母核） | 1985607-70-2 |
| 3-(Benzyloxy)-4-oxo-4h-pyran-2-carboxylic acid | 3-(芐氧基)-4-氧代-4H-吡喃-2-羧酸 | 119736-16-2 |
| 7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol | 7,8 -二氟- 6,11 -二氫-二苯并[ B,E ]噻吩并- 11 -醇 | 1985607-83-7 |
|
非奈利酮中間體 Finerenone Intermediates |
||
| 4-formyl-3-methoxybenzonitrile | 4-氰基-2-甲氧基苯甲醛 | 21962-45-8 |
| 4-amino-5-methylpyridone | 4-氨基-5-甲基-2-羥基吡啶 | 95306-64-2 |
| 2-cyanoethylacetoacetate | 2-氰基乙酰乙酸乙酯 | 65193-87-5 |
| 2-chloro-5-methylpyridin-4-amine | 2-氯-4-氨基-5-甲基吡啶 | 79055-62-2 |
|
阿帕他胺中間體 Apalutamide Intermediates |
||
| 5-Amino-3-(trifluoromethyl)picolinonitrile | 5-氨基-3-(三氟甲基)氰基吡啶 | 573762-62-6 |
| N-Boc-1-aminocyclobutanecarboxylic acid | Boc-1-氨基環(huán)丁烷羧酸 | 120728-10-1 |
| 1-amino-N-[6-cyano-5-(trifluoromethyl)-3-pyridinyl]Cyclobutanecarboxamide | 1-氨基-N-[6-氰基-5-(三氟甲基)-3-吡啶基]-環(huán)丁烷甲酰胺 | 1950587-17-3 |
|
磷酸蘆可替尼中間體 Ruxolitinib Phosphate Intermediates |
||
| 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | 1-(1-乙氧基乙基)-4-吡唑硼酸頻哪醇酯 | 1029716-44-6 |
| 3-Cyclopentylacrylonitrile | 3-環(huán)戊基丙烯腈 | 591769-05-0 |
| (4-(1-(2-Cyano-1-cyclopentylethyl)-1h-pyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate | (4-(1-(2-氰基-1-環(huán)戊基乙基)-1h-吡唑-4-基)-7h-吡咯并[2,3-d]嘧啶-7-基)特戊酸甲酯 | 1236033-05-8 |
|
烏帕替尼中間體 Upadacitinib Intermediates |
||
| (3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester | (3R,4S)-3-(2-溴乙酰基)-4-乙基-1-吡咯烷羧酸芐酯 | 1428243-26-8 |
| tert-butyl 5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-ylcarbamate | 5-甲苯磺?；?5H-吡咯并[2,3-B]吡嗪-2-胺基甲酸叔丁酯 | 1201187-44-1 |
| 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3-tosyl-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine | 8-((3S,4R)-4-乙基吡咯烷-3-基)-3-甲苯磺?；?3H-咪唑并[1,2-a]吡咯并[2,3-e]吡嗪 | 1428243-28-0 |
|
奧澤沙星中間體 Ozenoxacin Intermediates |
||
| ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate | 奧澤沙星中間體A | 103877-51-6 |
| 5-broMo-N,3-diMethylpyridin-2-aMine | 奧澤沙星中間體B | 245765-66-6 |
| [6-[benzoyl(methyl)amino]-5-methyl-3-pyridyl]boronic acid | 奧澤沙星中間體D | 446299-81-6 |
|
布林佐胺中間體 Brinzolamide Intermediates |
||
| (S)-3,4-dihydro-6-chloro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine-1,1-dioxide | (S)-6-氯-3,4-二氫-2H-噻吩并[3,2-e]-1,2-噻嗪-4-醇1,1-二氧化物 | 160982-16-1 |
| (S)-3,4-Dihydro-4-hydroxy-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide | (S)-3,4-二氫-4-羥基-2-(3-甲氧基丙基)-2H-噻吩并[3,2-e]-1,2-噻嗪-6-磺胺-1,1-二氧化物 | 154127-42-1 |
|
鹽酸阿替卡因中間體 Articaine hydrochloride Intermediates |
||
| 3-Amino-4-methyl-2-thiophene carboxylic acid methyl ester | 3-氨基-4-甲基噻吩-2-甲酸甲酯 | 85006-31-1 |
|
鹽酸羅哌卡因中間體 Ropivacaine Intermediates |
||
| N-(2,6-Dimethylphenyl)-2-piperidinecarboxamide | N-(2,6-二甲苯基)-2-哌啶甲酰胺 | 15883-20-2 |
| (2S)-N-(2,6-Dimethylphenyl)-2-piperidinecarboxamide | (S)-N-(2,6-二甲苯基)-2-哌啶甲酰胺 | 27262-40-4 |
|
別孕酮中間體
Brexanolone Intermediates
|
||
| Allopregnan-3β-ol-20-one acetate | 別孕烯醇酮醋酸酯 | 906-83-2 |
| 3β-hydroxy-5α-pregnan-20-one | 別孕烯醇酮 | 516-55-2 |
|
氟雷拉納中間體
Fluralaner Intermediates
|
||
| 4-acetyl-2-methylbenzoic acid | 2-甲基-4-乙?；郊姿?/span> | 55860-35-0 |
| 2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride | 2-氨基-N-(2,2,2-三氟乙基)乙酰胺鹽酸鹽 | 1171331-39-7 |
| 3',5'-DICHLORO-2,2,2-TRIFLUOROACETOPHENONE | 3', 5'-二氯-2, 2, 2-三氟苯乙酮 | 130336-16-2 |
|
阿福拉納中間體
Afoxolaner Intermediates
|
||
| 4-acetyl-1-naphthoic acid | 4-乙?；良姿?/span> | 131986-05-5 |
| 2-AMino-N-(2,2,2-trifluoroethyl)acetaMide hydrochloride | 2-氨基-N-(2,2,2-三氟乙基)乙酰胺鹽酸鹽 | 1171331-39-7 |
| 1-[3-Chloro-5-trifluoromethylphenyl]-2,2,2-trifluoroethanone | 1-[3-氯-5-(三氟甲基)苯基]-2,2,2-三氟乙酮 | 1125812-58-9 |
從現(xiàn)有原料藥基礎上進行制劑項目深度挖掘，形成細分領域專業(yè)化MAH路線，已開展11項MAH項目，其中舒更葡糖鈉項目已獲批，利丁卡因制劑已上報至國家局進入臨床研究階段。
CDMO業(yè)務可承接高端醫(yī)藥中間體、新型農(nóng)化類中間體、寵物藥等獸藥類中間體、大健康類跨界產(chǎn)品及中間體定制與服務。
聯(lián)系我們
山東誠匯醫(yī)藥集團有限公司
CHENGHUI PHARMACEUTICAL GROUP LTD
藥廠業(yè)務
沈經(jīng)理 0531-58897066
廖經(jīng)理 0531-58897055
貿(mào)易公司業(yè)務
李經(jīng)理 0531-58897086
黃經(jīng)理 0531-58897087
唐經(jīng)理 0531-58897051
獸藥業(yè)務
任經(jīng)理 0531-58897165
市場部
謝經(jīng)理 0531-58897070
人才招聘
李經(jīng)理 0531-58897028
郵箱
sales@jnchsd.com
market@jnchsd.com
官網(wǎng)：m.vltedu.com
